# Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer

> **NCT00417976** · PHASE2 · COMPLETED · sponsor: **Tony Bekaii-Saab** · enrollment: 42 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Bevacizumab
- **DRUG:** Infusional 5-Fluorouracil

## Key facts

- **NCT ID:** NCT00417976
- **Lead sponsor:** Tony Bekaii-Saab
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-12
- **Primary completion:** 2010-03
- **Final completion:** 2011-02
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2015-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00417976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00417976, "Gemcitabine, Infusional 5 Fluorouracil and Bevacizumab in Patients With Advanced Pancreas Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00417976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*